A rare opportunity, don't miss it!

Newco/Opportunities for going global have arrived! The DrugTimes BD team (BD@drugtimes.cn) currently has multipleWeight Loss and Muscle Gain Innovative DrugLooking for buyers, welcome to inquire.！

Full text, 2229 words, 0 images

Estimated reading time: 8 minutes

The pharmaceutical industry is slowly emerging from the trough.

According to incomplete statistics, nearly ten innovative drug companies completed financing in July alone. Among them, Orange Sail Pharmaceuticals secured the highest amount of funding. On July 28, 2025, this company, which focuses on bispecific/multi-specific antibodies, ADCs, and new molecular types, successfully closed a Pre-A+ round exceeding 60 million US dollars. Following closely behind is Lanabio, a subsidiary of Dongcheng Pharmaceuticals.(Focused on the field of nuclear medicine)Completed over 300 million RMB in C+ round financing. Additionally, there is TuoXin TianCheng's 40 million USD B round financing and Ribo Bio's over 200 million RMB in new private equity financing.

Entering August, the financing activities in the pharmaceutical field remain robust. According to incomplete statistics, several innovative drug companies, including Arthrosi and Zenitar, have completed financing. In the following sections, the author will introduce a few notable financing deals.

01

Artech Biotech Co., Ltd.

Recently, Atek Biotechnology Co., Ltd.("Hereinafter referred to as 'Arttech'")Announced the completion of Series A financing.

ArtechEstablishmentOfTargetYesBecomeGlobalLeadingTheProteinDegradationDrugR&DEnterprise，Its core technology is derived from the protein autophagy degradation technology published by Fudan University in the main issue of "Nature" in 2019.（ATTEC）Currently, Atek has reached a cooperation with global pharmaceutical giants, and its neurodegenerative disease pipeline developed based on the ATTEC platform has gained international recognition.ItsFirst LaunchPipelineATCN1001 is a molecular glue drug targeting Parkinson's disease. Compared with other drugs under clinical research, it has the advantages of small molecular weight, good drug-like properties, low cost, and strong ability to cross the blood-brain barrier.Atech is actively promotingThis moleculeTheImprovementOptimizationAnd IND application plan.

It is reported that this round of financing was jointly invested by the Shanghai Biomedical Innovation and Transformation Fund under Shangshi Capital and the Fudan University Biomedical Transformation Fund under Fufu Capital. The funds raised will be used to improve and optimize new molecular glue drugs and advance the preclinical research of candidate molecules in Parkinson's disease.

August 5, 2025, Zenitar(hereinafter referred to as "Zenitar")Announced the completion of nearly 400 million RMB in financing led by Qiming Venture Partners, with participation from Gaorong Capital, Jiyuan Capital, Qiji Investment, FiveSource Capital, and Zhongyuan Investment. Sichuan Biomedical Industry Group continued its investment.

Zenitar, founded in 2019, is an innovative drug research and development company driven by structural biology and artificial intelligence, focusing on key therapeutic areas such as oncology, autoimmune diseases, inflammation, and neurological disorders.

Currently, Zenitar has independently developed seven globally-licensed products with differentiation and international competitiveness, establishing a pipeline covering multiple major disease areas. Among these, one indication has entered pivotal Phase III clinical trials, and five indications have progressed to Phase II clinical trials.

According to the announcement on its official website, the funds from this round of financing will be mainly used to advance several innovative drugs with global competitiveness into pivotal Phase III clinical trials and to support the continuous expansion of new R&D pipelines.

August 7, 2025, Shanghai Hezhou Pharmaceutical Co., Ltd.(hereinafter referred to as "Hezhou Pharmaceutical")Announced the completion of a multi-million dollar Series A round of financing.

Shanghai Hezhou Pharmaceutical Co., Ltd. was founded in 2022 and incubated by a seasoned investment team.Focus on Innovative Targeted Radioligand Drugs（ RLT）A company dedicated to the research, innovation, and industrialization of next-generation radiopharmaceuticals.According to reports，ItsCurrentlyAlreadyThroughDifferentiated target selection strategies and innovative radionuclide platform technology as core competitiveness have successfully built multiple radioactive drug pipelines centered around the α nuclide Pb-212. Currently, several first-in-class...(FIC)Or best-in-class（BIC）The global rights pipeline with potential has made significant progress, and the leading product has obtained positive human trial data in the clinical stage.

According toShanghai Hezhou Pharmaceutical Co., Ltd.PharmaceuticalsAnnouncement，This round of financing will accelerate the development of Shanghai Hezhou Pharmaceutical Co., Ltd.'s pipeline, continuously upgrade its innovative radiopharmaceutical discovery platform, build an end-to-end radiopharmaceutical supply chain, and support the company’s rapid growth in the radiopharmaceutical field.

2025Year8Month7Day，Minghui Pharmaceutical Ltd. Announces Completion of $131 Million Pre-IPO Financing Round.

Minghui Pharmaceutical Ltd. is a late-stage clinical innovative biopharmaceutical company focusing on the fields of oncology and immune-related diseases.The company's core products include: an innovative topical JAK inhibitor for which an application has been submitted in China; a subcutaneous injectable IGF-1R antibody for the treatment of thyroid eye disease, currently in Phase III clinical trials; a PD-1/VEGF bispecific antibody in Phase II clinical stage, being evaluated in combination with TROP2 ADC; and a B7-H3 ADC for second-line treatment of small cell lung cancer, currently in Phase III clinical stage. Both ADC products demonstrate strong best-in-class potential.

According to reports，Minghui Pharmaceutical Ltd.MinghuiPharmaceuticalsOfThis round of financing was led by OrbiMed, a globally renowned healthcare investment firm, and co-led by Qiming Venture Partners. Existing shareholder TF Capital continued its support. Additionally, several high-quality institutional investors were brought in, including Boyuan Capital, 5Y Capital, Shizhen Capital, and Junyi Investment. Representatives from OrbiMed and Qiming Venture Partners will join the company's board of directors.

This round of financing will be mainly used to accelerate the advancement of the company's core projects in the clinical stage, with a focus on supporting PD-1/VEGF bispecific antibodies and their antibody-drug conjugates.（ADC）The joint treatment development strategy, which will also be used for the launch preparation and commercialization process of topical JAK inhibitors in China.

Recently, Zhejiang Haichang Biotech Co., Ltd.("Haichang Biotech" for short)Announced the completion of Series C financing.

Haichang Biotechis a company driven by the core force of biopharmaceutical technology innovation,The product pipeline covers multiple disease areas, including oncology, metabolic diseases, pain management, and infectious diseases.ItsFocusing on the development and industrial application of drug delivery system technologies, we have built technology platforms with independent intellectual property rights, such as QTsome.Currently，ItsSelf-developedOfThe Innovative Small Nucleic Acid Drug HC0301 for Primary Liver Cancer Has Entered China(Including Hong Kong, China), international multi-center Phase II clinical trials in the United States, etc.,YesOne of the fastest progressing pipelines in the global small nucleic acid precision oncology treatment field. HC016 Lipid Complex Injection, a next-generation TLR9 immune agonist based on QTsome delivery technology, has obtained IND approvals in both China and the U.S., entering Phase I clinical trials, with BIC potential.Quality. Meanwhile, the company has several potential FIC nucleic acid drug pipelines under research, as well as innovative therapies like in vivo cell editing therapies.

Its total funding in this round is nearly 500 million RMB, led by SDIC (State Development & Investment Corp).(Guangdong)Technology Transfer Venture Capital Fund leads the investment, Jianyuan Shunda(Hangzhou)Equity investment funds, Dongguan Songshan Lake Science City Equity Investment Fund, Zhejiang Province's "4+1" Biopharmaceuticals and High-End Medical Devices Industry Fund, and Kexing Biopharmaceutical Co., Ltd. jointly participated. The funds from this round of financing will be mainly used for the development of nucleic acid innovative drug pipelines, research and clinical trials of new extrahepatic delivery systems, and the acceleration of production base and capacity construction.

Summary

Overall, the recovery of this round of investment and financing in China's pharmaceutical enterprises is mainly driven by favorable policies.

Just the day before yesterday, on August 5, 2025, seven departments including the People's Bank of China, the Ministry of Industry and Information Technology, the National Development and Reform Commission, and the Ministry of Finance jointly issued the "Guiding Opinions on Financial Support for New Industrialization" (hereinafter referred to as the "Opinions"). The Opinions propose to leverage the incentive role of structural monetary policy tools to guide banks in providing medium- and long-term financing for key industrial chains and technological product research in manufacturing sectors such as medical equipment and advanced materials; support qualified enterprises in emerging industries like high-end equipment and biomedicine to raise funds in multi-level capital markets. It is believed that under this round of incentives, there is still room for growth in pharmaceutical investment and financing.

References:

1. EachOfficial Website

2.Other Public Information

Image Source: Jimo AI

Copyright Statement/Disclaimer

This is a summary article.

This article is for informational exchange purposes only and does not provide any commercial, medical, or investment advice.

The images, videos, fonts, music, and other materials in the article are either authorized genuine works purchased by Yaotimes, sourced from the WeChat public image library, taken from the company's official website or the Internet, or used in accordance with the CC0 protocol. The copyright belongs to the respective owners, and Yaotimes makes every effort to acknowledge the sources.

If you have any questions, please contact us.

Sincerely thank you!

DrugTimes Official Website: www.drugtimes.cn

Contact Information:

Phone: 13651980212

WeChat: 27674131

Email: contact@drugtimes.cn

Click here to view more highlights!